The proportion of IPF and control cohorts reporting use of statins was similar (53.3% and 50.0%, respectively), but more patients in the IPF cohort were taking H2 blockers, anticoagulants, bronchodilators, and insulin. This evidence concerns the gene INS and idiopathic pulmonary fibrosis.